Speakers

Shouhao Zhou

Associate Professor of Biostatistics, College of Medicine, Pennsylvania State University

View presentation and abstract: Evidence Synthesis of Drug Safety from Oncology Trials

Biography

Shouhao Zhou is an Associate Professor of Biostatistics at Penn State College of Medicine, where he also directs the Center for Methodology Excellence and Innovation and the Biostatistics PhD Program. He received his PhD in Statistics from Columbia University and previously served on the faculty at The University of Texas MD Anderson Cancer Center. His research focuses on Bayesian statistical methods, evidence synthesis, pharmacovigilance, and innovative cancer trial designs.


Yasuhiro Fujiwara

Chief Executive, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

View keynote presentation and abstract: The Future of Oncology Drug Development: A Regulatory Perspective from Japan

Biography

Yasuhiro Fujiwara

Dr Yasuhiro Fujiwara has been Chief Executive of the Pharmaceuticals and Medical Devices Agency (PMDA) since 2019. He actively engages with international regulatory agencies, including the International Coalition of Medicines Regulatory Authorities (ICMRA) for which he served as Vice-Chair from 2019 to 2025. Under his leadership, PMDA has strengthened regulatory collaboration with authorities across Asia, Europe, and North America.

A medical oncologist specializing in breast cancer, Dr Fujiwara was previously Director-General of the Strategic Planning Bureau of the National Cancer Center, and Deputy Director of the National Cancer Center Hospital. Between Jan 2011 and Feb 2013, he was Deputy Secretary-General of the Office of Medical Innovation, Cabinet Secretariat of Japan, and led health policy issues regarding life sciences.

Dr Fujiwara has authored or co-authored over 280 original articles in peer-reviewed journals including Nature Reviews Drug Discovery, Lancet Oncology, Journal of Clinical Oncology, and Annals of Oncology.


Hongyu Zhao

Ira V. Hiscock Professor of Biostatistics, Yale University

View keynote presentation and abstract: Omics Data in Oncology Trials

Biography

Hongyu Zhao

Dr. Hongyu Zhao is the Ira V. Hiscock Professor of Biostatistics, Professor of Statistics and Data Science, and Professor of Genetics at Yale University. His research interests are the development and application of statistical and computational methods to address scientific questions in genetics, molecular biology, drug development, and precision medicine. Some of his recent projects include single-cell data analysis, spatial transcriptomics, genome-wide studies to identify genetic variants underlying complex diseases, disease risk prediction using biobank data, QTL analysis, foundation models, biological network modeling and analysis, disease biomarker identification, and cancer genomics. Many of his methods are motivated by and applied to cancer research.


Chenguang Wang

Head of Quantitative Innovation and Statistical Strategy (QISS), Regeneron

View presentation title and abstract: Optimized Adaptive Oncology Clinical Trials with a Surrogate Endpoint-Based Drop-The-Losers Design

Biography

Chenguang Wang

Dr. Chenguang Wang is the Head of Quantitative Innovation and Statistical Strategy (QISS) at Regeneron. Previously, he served as an Associate Professor at Johns Hopkins University and worked as a Mathematical Statistician at the Center for Devices and Radiological Health (CDRH), FDA. Dr. Wang has extensive experience in clinical trial design and analysis, particularly in regulatory settings. He is also an elected Fellow of the American Statistical Association.


Kan Yonemori

Director of Medical Oncology, National Cancer Center Hospital (NCCH), Tokyo, Japan

View keynote presentation: How we utilize Artificial Intelligence for field of medical practice and oncology.

Biography

Kan Yonemori

Kan Yonemori is JSMO board certified-medical oncologist. He is Director of Medical Oncology at National Cancer Center Hospital (NCCH), Tokyo, Japan since 2020. Also Directors of both Department of Clinical Drug Development, and Division of International Medical Service (Since 2023) and Deputy Director of International Clinical Development Division (since 2015) of NCCH. He worked for the Pharmaceuticals and Medical Devices Agency in 3 years. He studied as visiting fellow in Investigational Drug Branch, Cancer Therapy Evaluation Program, US National Cancer Institute, US Food and Drug Administration in 2013. He dedicate in clinical trial for solid tumor, breast cancer, gynecologic cancer, urological cancer and sarcoma from phase I to phase III.


Kohei Uemura

Biostatistics & Bioinformatics program, Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan

View presentation and abstract in Invited Session 1

Biography

Kohei Uemura

Kohei Uemura is an Associate Professor of Biostatistics at The University of Tokyo and a Director at Statcom, Inc. He previously worked as a statistical reviewer at Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for eight years. His research focuses on statistical methods for clinical trials, particularly adaptive designs, Bayesian methods, platform trials, and trials in rare diseases.


J. Jack Lee, PhD

Department of Biostatistics, The University of Texas MD Anderson Cancer Center

View abstract in Invited Session 1

J. Jack Lee
Biography

J. Jack Lee, PhD, MS, DDS, is Professor of Biostatistics and the John G. & Marie Stella Kenedy Foundation Chair in Cancer Research at The University of Texas MD Anderson Cancer Center. He also directs MD Anderson's Biostatistics Resource Group. His research focuses on the design and analysis of cancer clinical trials, including Bayesian adaptive designs, statistical methods for precision medicine, drug-combination studies, and biomarker identification and validation. During more than 30 years at MD Anderson, Dr. Lee has collaborated with multidisciplinary teams across clinical, translational, and basic science research. He is a Fellow of the American Statistical Association, the Society for Clinical Trials, and the American Association for the Advancement of Science. He has published extensively in statistical and medical journals and co-authored books on Bayesian adaptive clinical-trial methods and model-assisted Bayesian dose-finding and optimization designs.


Junki Mizusawa, PhD

Section Chief of Biostatistics, Center for Research Administration and Support, National Cancer Center Japan

View moderator profile in Invited Session 1

Junki Mizusawa
Biography

Junki Mizusawa, PhD, is Section Chief of Biostatistics at the Center for Research Administration and Support, National Cancer Center Japan (NCCJ). With more than 15 years of experience, he has played a central role as a trial statistician in the Japan Clinical Oncology Group (JCOG), contributing to the planning, analysis, and publication of numerous multi-institutional confirmatory cancer clinical trials. His work has focused on multicenter trials in gastrointestinal, hepatobiliary and pancreatic, head and neck, and brain tumors, as well as investigator-initiated studies. Dr. Mizusawa received his PhD from Tokyo Medical and Dental University in 2024. His research interests include master protocols, quality of life, and pragmatic trials.


Toshiki Masuishi, MD, PhD

Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan

View abstract in Invited Session 1

Toshiki Masuishi
Biography

Toshiki Masuishi, MD, PhD, is a medical oncologist in the Department of Clinical Oncology at Aichi Cancer Center Hospital, Japan, specializing in gastrointestinal cancers. He serves as Vice Chair of the Basket Trial Committee of the West Japan Oncology Group (WJOG) and has led several investigator-initiated clinical trials. His work includes biomarker-driven basket trials evaluating brigatinib for ALK fusion-positive solid tumors and necitumumab-based therapy for EGFR-amplified solid tumors. His research focuses on developing new treatment strategies for gastrointestinal cancers and advancing precision oncology through clinical trials targeting rare molecular alterations.


Hiroya Taniguchi, MD, PhD

Head Physician, Department of Clinical Oncology, Aichi Cancer Center Hospital, Japan

View abstract in Invited Session 1

Hiroya Taniguchi
Biography

Hiroya Taniguchi, MD, PhD, is Head Physician in the Department of Clinical Oncology at Aichi Cancer Center Hospital, Japan, specializing in gastrointestinal cancers. From 2018 to 2021, he worked at the National Cancer Center Hospital East and contributed to the SCRUM-Japan, GOZILA, and CIRCULATE-Japan precision oncology projects. He served as coordinating investigator of the ctDNA-guided HERALD basket trial and has led several investigator-initiated trials in colorectal cancer. His current work focuses on decentralized and pragmatic approaches to improving clinical trial access and efficiency.


Chao A. Hsiung, PhD

Investigator Emeritus, Institute of Population Health Sciences, National Health Research Institutes, Taiwan

View moderator profile in Invited Session 4

Biography

Chao Agnes Hsiung

Dr. Chao Agnes Hsiung is an Investigator Emeritus and had been a distinguished investigator at the Institute of Population Health Sciences, National Health Research Institutes (NHRI), Taiwan. She received her Ph.D. from Columbia University. She was a Research Fellow at Academia Sinica (1985-1997) before joining NHRI. She was the founding director of the Division of Biostatistics and Bioinformatics at NHRI from 1997-2008, and founding director of the Institute of Population Health Sciences from 2008-2020. Dr. Hsiung has made seminal contributions to the areas: (i) non-smoking female lung cancer genetic epidemiological studies; (ii) The Healthy Aging Longitudinal Study in Taiwan (HALST); (iii) bioinformatics; and (iv) health policy in Taiwan. She has played a leading role in several large-scale integrated epidemiological studies, such as Genetic Epidemiological Study of Lung Adenocarcinoma (GELAC) in Taiwan, Healthy Aging Longitudinal Study in Taiwan (HALST). She is also the Program Director of the Bioinformatics Core Facility for Biomedical and Biotechnology R&D sponsored by the National Science and Technology Council (NSTC).


Takashi Kohno, PhD

Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Japan

View abstract in Invited Session 4

Takashi Kohno
Biography

Dr. Takashi Kohno began his career as a researcher in the Biology Division at the National Cancer Center Research Institute (NCCRI) in 1995. He became Section Head of the Biology Division in 2000 and Chief of the Division of Genome Biology in 2011. From 2018 to 2023, he was Section Head in the Section of Data Science Strategy at the Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center. In 2023, he was appointed Director of C-CAT, where he oversees advanced cancer genomics research and therapy development. His key accomplishments include identifying RET fusion as a novel therapeutic target and implementing NCC Oncopanel, a comprehensive genomic profiling test.


Kouya Shiraishi, PhD

Department of Clinical Genomics, National Cancer Center Research Institute, Japan

View abstract in Invited Session 4

Kouya Shiraishi
Biography

Since 2008, Dr. Kouya Shiraishi has served as a researcher and laboratory head in the Division of Genome Biology at the National Cancer Center Research Institute, where he has conducted genomic analyses of germline variants in lung cancer. In 2022, he was appointed Chief of the Department of Clinical Genomics. Through genome-wide association studies, he identified several lung adenocarcinoma susceptibility loci and characteristics of EGFR-mutation-positive lung adenocarcinoma in Asian populations. He currently conducts genomic epidemiological research that combines omics data with lifestyle information to identify high-risk groups more accurately. He also serves as a council member and associate editor of the Japanese Cancer Association and Vice Chair of the Biobank Committee at the National Cancer Center.


I-Shou Chang, PhD

National Institute of Cancer Research, National Health Research Institutes, Taiwan

View abstract in Invited Session 4

I-Shou Chang
Biography

I-Shou Chang is an Investigator Emeritus at the National Institute of Cancer Research, National Health Research Institutes (NHRI), Taiwan. He earned his PhD in Mathematics from Columbia University in 1976. He was an associate professor and professor in the Department of Mathematics at National Central University, Taiwan, from 1976 to 2002, and a visiting professor in the Department of Mathematical Statistics at Columbia University from 1989 to 1990. At NHRI, he served as an investigator in the President's Laboratory and the National Institute of Cancer Research, as Director of the Department of Research Resources and Biomedical Research Resources, and as Director of the Department of Academic Planning. His research interests include cancer epidemiology, cancer risk prediction, and multi-omics studies.


Chao-Hua Chiu, MD

Taipei Medical University Hospital, Taiwan

View abstract in Invited Session 4

Chao-Hua Chiu
Biography

Dr. Chao-Hua Chiu is Professor of Medicine, Vice Superintendent at Taipei Cancer Center, and Director of the Clinical Research Center at Taipei Medical University Hospital, Taipei Medical University, Taiwan. He earned his MD from Taipei Medical University and completed dual specialty training in pulmonology and medical oncology at Taipei Veterans General Hospital. From 2006 to 2008, Dr. Chiu served as a visiting scientist in the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center. He later directed the Section of Thoracic Oncology at Taipei Veterans General Hospital from 2016 to 2022 before assuming his current leadership roles at Taipei Medical University. His clinical work and research interests focus on low-dose CT lung cancer screening, targeted therapies, and clinical trials for thoracic malignancies.


Chin-Fu Hsiao, PhD

Investigator, Institute of Population Health Sciences, National Health Research Institutes, Taiwan

View moderator profile in Invited Session 2

Biography

Chin-Fu Hsiao

Dr. Hsiao is an Investigator at the Institute of Population Health Sciences, National Health Research Institutes (NHRI), Taiwan. His research interests focus on Bayesian decision theory, adaptive clinical trial design, multiregional clinical trials, and basket trial methodology. In addition to his research, he leads the statistical and data management activities for investigator-initiated clinical trials at NHRI, overseeing study design, data management, statistical analysis, and regulatory reporting to ensure the integrity and quality of clinical research. He also collaborates extensively with multidisciplinary clinical investigators in the design, conduct, and analysis of clinical trials.


Hui-Jen Tsai, MD, PhD

Investigator and Attending Physician, National Institute of Cancer Research, National Health Research Institutes

View presentation and abstract in Invited Session 2

Biography

Hui-Jen Tsai

Dr. Hui-Jen Tsai is an Investigator and Attending Physician in National Institute of Cancer Research, National Health Research Institutes. She received her MD degree and PhD degree at Kaohsiung Medical University. She is a medical oncologist with clinical expertise in neuroendocrine tumors and thyroid cancer. She joined National Health Research Institutes in 2011 and did researches on neuroendocrine tumors from epidemiologic, translational, and clinical aspects, and identifying novel therapeutic targets for leukemia and solid tumors. She is also dedicated to clinical trials and is the principal investigator of several early phase investigator initiated trials (IIT) and pharma-sponsored phase III trials. She is the director of Taiwan Cooperative Oncology Group, which sponsors and overlooks the conduction of IITs in Taiwan.


Tzy-Chy Lin, MD, PhD

Statistical Section Chief, Division of New Drugs, Center for Drug Evaluation, Taiwan

View presentation and abstract in Invited Session 2

Biography

Tzy-Chy Lin

I currently serve as the Statistical Section Chief in the Division of New Drugs at the Center for Drug Evaluation, where I am primarily responsible for the statistical review of Investigational New Drug applications (INDs) and New Drug Applications (NDAs). My work covers clinical trial design, sample size determination, interim analyses, multiplicity adjustment, handling of missing data, sensitivity analyses, and statistical interpretation of efficacy results. I also provide professional statistical consultation to help ensure the scientific validity and appropriateness of trial designs and analytical methods.

During my tenure, I have been invited to speak or serve as a panelist at numerous domestic and international conferences related to clinical trials, biostatistics, and pharmaceutical regulation, where I share practical experience in clinical trial design, statistical methodology, and regulatory review. I have also participated in international regulatory and scientific activities, including the ICH E11A Working Group, contributing to the discussion and development of international clinical trial guidelines.

In addition, I serve as an adjunct assistant professor at National Taipei University and as a member of an Institutional Review Board, where I am involved in statistical education as well as the scientific and ethical review of human research. My professional interests focus on advances in clinical trial methodology, drug development, and regulatory science, with the goal of continuously improving the quality of statistical analysis and regulatory review through the integration of regulatory, academic, and international experience.


Shunsuke Shiota, MMSc

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

View abstract in Invited Session 2

Shunsuke Shiota
Biography

Shunsuke Shiota, MMSc, is a biostatistics reviewer in the Office of New Drug V at the Pharmaceuticals and Medical Devices Agency (PMDA), Japan. He is responsible for the statistical review of anticancer drug applications, with a focus on the design, analysis, and interpretation of confirmatory oncology clinical trials.


Kenichi Nakamura, MD, PhD, MBA

Chief, Department of International Clinical Development, and Executive Advisor to the Hospital Director, National Cancer Center Hospital, Tokyo, Japan

View abstract in Invited Session 2

Kenichi Nakamura
Biography

Kenichi Nakamura, MD, PhD, MBA, is Chief of the Department of International Clinical Development and Executive Advisor to the Hospital Director at the National Cancer Center Hospital, Tokyo, Japan. He received his medical degree from Kyoto University in 1999, a PhD in Surgical Oncology from Kyoto University in 2016, and an MBA from GLOBIS University in 2022. After seven years of surgical training, he joined the National Cancer Center to participate in the management and operation of the Japan Clinical Oncology Group (JCOG), Japan's largest cancer clinical trial group. Since 2015, he has led the development of a department that supports investigator-initiated registration trials at the National Cancer Center Hospital. In 2020, Dr. Nakamura initiated the ATLAS project to establish a multinational clinical trial network across Asian countries. His work also focuses on decentralized clinical trials, the application of generative AI to clinical trial processes, and modernization of Japan's clinical trial regulations.


Yuki Ando, PhD

Principal Senior Scientist for Biostatistics, Pharmaceuticals and Medical Devices Agency, Japan

Yuki Ando
Biography

Dr. Yuki Ando is a Principal Senior Scientist for Biostatistics at the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. She has over 20 years of experience in the biostatistical review of pharmaceutical and medical device products and currently leads biostatistical review and consultation for new drug and medical device applications at PMDA.

In addition to her regulatory review responsibilities, she contributed to several projects across multi-offices in PMDA, including the Real-World Data (RWD) Working Group and the Multi-Regional Clinical Trials (MRCT) Working Group. She also played a leading role in regulatory and standardization efforts related to the submission and utilization of electronic study data in new drug applications.

Dr. Ando previously served as a member of the ICH E9(R1) and E8(R1) Expert Working Groups (EWG) and is currently contributing to the development of ICH E20 as a member of the EWG.

She received a Master's degree in Engineering from Tokyo University of Science and a Ph.D. in Health Sciences from Osaka University.


Justine Rochon

Senior Vice President, Head of R&D Data and Quantitative Sciences, Takeda

Justine Rochon
Biography

Dr. Justine Rochon leads Takeda's R&D Data and Quantitative Sciences organization, advancing data-driven decision-making across quantitative pharmacology, translational sciences, patient safety and pharmacovigilance, clinical data sciences, advanced statistics, and AI integration. A psychologist and biostatistician with more than 20 years of experience in academia and industry, she holds a doctorate from the Medical Faculty of Heidelberg University. Dr. Rochon champions the responsible use of AI in drug development and co-authored the Charter for Data Science in Pharmaceutical R&D and the Manifesto for AI-Driven Clinical Trials.

She is a former President of EFSPI (European Federation of Statisticians in Pharmaceutical Industry), serves on the ASA Biopharmaceutical Section Executive Board, co-founded the DISRUPT-DS (Data Science) Roundtable, and was named a 2025 Trailblazing Woman in Pharma by Reuters.

LinkedIn profile


Satoshi Hattori

Department of Biomedical Statistics, Graduate School of Medicine, The University of Osaka, Japan

View presentation and abstract in Invited Session 8 · View proposer profile in Invited Session 5 · View moderator profile in Keynote Session 4

Biography

Satoshi Hattori

Satoshi Hattori is Professor of Biostatistics at The University of Osaka, Japan. His research focuses on statistical methodology for clinical trials and evidence synthesis, with particular interests in survival analysis, meta-analysis, causal inference, and methods for addressing publication bias. He has contributed to the development of statistical methods for the design and analysis of clinical studies, particularly in oncology. He is currently President of the Japanese Region of the International Biometric Society.


Shannon McWeeney

Professor, Oregon Health & Science University

View presentation in Invited Session 7 · View moderator profile in Keynote Session 3

Biography

Shannon McWeeney

Dr. Shannon McWeeney, Professor at Oregon Health and Science University (OHSU), is a methodologist working at the intersection of computer science, biostatistics and genetics to develop approaches to solve research bottlenecks and novel ways to visualize and interpret information. Her work on novel computational methods and frameworks for prioritization is one of her most significant contributions to science. While these methods were initially applied to precision medicine (cancer), they have wide applicability for target identification and therapeutic prioritization for many complex traits. In 2010, Dr. McWeeney was selected as a Kavli Frontiers Fellow by the US National Academy of Sciences for these contributions. Dr. McWeeney is the inaugural Chief Data Officer and Associate Director of Data Science for the OHSU Knight Cancer Institute and has a career-long commitment to data sharing and patient engagement. She served as a member of the Enhanced Data Sharing working group for the NCI Blue Ribbon Panel for White House Moonshot Initiative and as a member of the Biden Cancer Initiative Data Sharing and Patient Empowerment workstream. In 2020, she was named the Director of Medical Bioinformatics for the OHSU Knight Precision Oncology Program, in which she is responsible for the hardening and validation of assays, algorithms and models in the transition from research analytics to CLIA. She is a M-PI for OHSU’s NCI Acquired Resistance to Therapy Network (ARTNet), which arose from her collaborative work for over a decade as part of the OHSU BeatAML program. She is also an MPI for the NIH Bridge2AI AI-READi Salutogenesis Data Generation Project, collaboratively working to develop automated tools to accelerate the creation of FAIR (Findable, Accessible, Interoperable, and Reusable), CARE (Principles for Indigenous Data Governance) and ethically sourced data sets for machine learning and artificial intelligence.


Yong Chen, PhD

Professor of Biostatistics and Biomedical Informatics, University of Pennsylvania Perelman School of Medicine

View presentation in Invited Session 7

Yong Chen
Biography

Dr. Yong Chen is Professor of Biostatistics and Biomedical Informatics at the University of Pennsylvania Perelman School of Medicine and Founding Director of the PennCIL Lab (Penn Computing, Inference and Learning) and a type-I center CHASE (Center for Health AI and Synthesis of Evidence) with 30 trainees and staff. His research focuses on distributed inference and federated learning for multi-institutional collaborations, causal machine learning and translational sciences. His work on real-world data has been featured by The New York Times and TIME, and one of the studies he led was selected as a Top 10 Clinical Research Achievement in the US by the Clinical Research Forum in 2026. He is an elected fellow of the ASA, IMS, ACMI, AMIA, ISI, and RSM.


Hidewaki Nakagawa

RIKEN

View presentation in Invited Session 7

Biography

Hidewaki Nakagawa

Dr. Nakagawa graduated from Osaka University and completed training in clinical oncology as a GI surgeon. After obtaining his PhD for hereditary cancer, he had postdoctoral training (1999-2003) for cancer genomics at Ohio State University, USA. In 2003, he returned to Japan as an assistant professor at The University of Tokyo, where he was dedicated to therapeutic target screening for cancers. In 2008, he moved to RIKEN as a team leader of genomic medicine and his research has been focusing on cancer hereditability and cancer whole genome sequencing for GI cancers, liver cancer, and urological cancers. He has been working for international large-scale cancer genome sequencing project ICGC/TCGA. He is now interested in cancer immuno-genomics by single-cell and spatial technologies and medical implementation of genomic technologies.


Shivaani Kummar, MD

Director, Knight Cancer Institute, Oregon Health & Science University

View moderator profile in Keynote Session 1 · View moderator profile in Invited Session 7

Biography

Shivaani Kummar

Dr. Shivaani Kummar is Director, Knight Cancer Institute, Chief Scientific and Academic Officer, Knight Cancer group, Margaret and Lester DeArmond Chair of Molecular Oncology, Division Chief of Hematology and Medical Oncology, co-Director of the Center of Experimental Therapeutics, Oregon Health & Science University (OHSU), Portland, Oregon, USA.

Prior to joining OHSU in 2020, she was on faculty at Yale University Cancer Center (2000-2004), served as Head, Developmental Therapeutics Clinic, National Cancer Institute, NIH (2004-2011), Head of Early Clinical Trials Development Office of the Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH (2011-2015), Professor of Medicine and Director of the Phase 1 Clinical Research Program and Translational Oncology Program at Stanford University, Palo Alto, California (2015-2020).

She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. She has authored 200 peer reviewed publications, 9 book chapters, and co-edited a book on ‘Novel Designs of Early Phase Trials for Cancer Therapies’. She is a member of the Scientific Planning Committee, American Society of Clinical Oncology (ASCO), member, National Cancer Policy Forum, National Academies of Sciences, Engineering and Medicine, Member, among others.


Timothy J. Taxter, MD, MBA

Executive Medical Director of Algorithmic Diagnostics, Tempus AI

View presentation in Invited Session 7

Biography

Timothy J. Taxter

Dr Taxter is the Executive Medical Director of Algorithmic Diagnostics at TempusAI where he leads the development and clinical deployment of diagnostic, prognostic and predictive biomarkers in oncology as laboratory developed tests or companion diagnostics for pharmaceutical and biotech partners. Dr Taxter is also an advisor for Portal Innovations and Artan Bio, and Director of translation research for the American Board of Precision Medicine. Dr Taxter attended Fellowship in Development Therapeutics and residency in Clinical Pathology at Northwestern Memorial Hospital. Dr Taxter attended Internal Medicine internship at University of Illinois at Chicago. Dr Taxter received his B.S. in Biology and M.D. from the University of Florida. Dr Taxter received his MBA from the Kellogg School of Management and was a Zell fellow.


Kanji Komatsu

Pharmacometrics Methodology Expert, Astellas Pharma Inc.

View presentation and abstract in Invited Session 3

Biography

Kanji Komatsu is a Pharmacometrics Methodology Expert at Astellas Pharma Inc. He has 25 years of experience in the pharmaceutical industry, working in the areas of pharmacokinetics, clinical pharmacology, and pharmacometrics. His work focuses on methodological research and the application of quantitative approaches in clinical drug development, particularly in pharmacometrics and its interface with biostatistics. He has experience in population pharmacokinetic/pharmacodynamic modeling, exposure-response analysis, and quantitative approaches to dose optimization. His recent interests include the integration of statistical methodology into pharmacometric analyses and interdisciplinary collaboration between pharmacometricians and statisticians.


Marc Buyse

IDDI and One2treat, Louvain-la-Neuve, Belgium; I-BioStat, Hasselt University, Belgium

View presentation and abstract in Invited Session 3 · View Keynote Session 2

Biography

Marc Buyse

Marc Buyse holds degrees in engineering, management, statistics and a ScD in biostatistics from the Harvard School of Public Health. He worked at the European Organization for Research and Treatment of Cancer (EORTC) in Brussels and at the Dana Farber Cancer Institute in Boston, MA, prior to founding IDDI, CluePoints and One2Treat, companies offering services and software for clinical research. He is Associate Professor of biostatistics at Hasselt University in Belgium. He has co-authored several books and ~ 500 peer-reviewed papers on statistical methods for surrogate endpoint validation, detection of errors in clinical data, analysis of multiple prioritized outcomes for patient-centric medicine. He proposed the Net Treatment Benefit as a measure of treatment effect in randomized clinical trials (see Marc E Buyse - Publications List).


Tony Jiang, PhD

Head of Statistical Science, Integrated Oncology, Astellas Pharma

View moderator profile in Invited Session 3

Biography

Tony Jiang

Dr. Tony Jiang is Head of Statistical Science, Integrated Oncology at Astellas Pharma. In this role, he provides statistical leadership across Astellas’ oncology and hematology pipeline and leads statistical teams supporting clinical development programs. Dr. Jiang earned his PhD in Statistics from the University of Connecticut and brings extensive expertise in oncology drug development, clinical trial methodology, and Bayesian statistics.


Yeonhee Park, PhD

Associate Professor, Department of Statistics, Sungkyunkwan University, South Korea

View presentation and abstract in Invited Session 3

Biography

Yeonhee Park

Dr. Yeonhee Park is an Associate Professor in the Department of Statistics at Sungkyunkwan University, South Korea, where she has been a faculty member since March 2025. Previously, she was an Assistant Professor in the Department of Biostatistics and Medical Informatics at the University of Wisconsin–Madison, where she also served as Director of the Biostatistics Shared Resource. Her research focuses on clinical trial design, precision medicine, dimension reduction, multivariate analysis, and Bayesian methods.


Masahiro Kojima, PhD

Associate Professor, Department of Data Science for Business Innovation, Chuo University, Japan

View presentation and abstract in Invited Session 3

Biography

Masahiro Kojima

Masahiro Kojima is an Associate Professor in the Department of Data Science for Business Innovation at Chuo University, Japan, and a Visiting Associate Professor at the Institute of Statistical Mathematics. He joined Kyowa Kirin in 2014 and received his Ph.D. in Statistical Science from the Graduate University for Advanced Studies (SOKENDAI) in 2022. He joined Chuo University in 2025 and now focuses primarily on his academic role, while continuing to work at Kyowa Kirin on a reduced-hours basis. His research focuses on statistical methods for clinical trials, particularly adaptive designs and dose optimization in early-phase oncology. Drawing on his experience in both industry and academia, he emphasizes developing intuitive, practical methods that can be readily implemented in clinical development.


Elizabeth Fox

St. Jude Children’s Research Hospital

View Plenary Session 1

Biography

Elizabeth Fox

Senior Vice President, Clinical Research Administration
Comprehensive Cancer Center, Associate Director of Clinical Research
Member, Department of Oncology

Dr. Fox leads clinical research prioritization, strategy, and operations at St Jude Children's Research Hospital. Nationally, she is the chair of Developmental Therapeutics Committee for the Children’s Oncology Group and the Pediatric Early Phase Clinical Trials Network. Dr. Fox has expertise in quantitative clinical and pre-clinical pharmacology, pediatric clinical oncology, and clinical research and trial design including response and toxicity biomarker endpoint development. She applies an integrative approach to clinical drug development utilizing animal models, pre-clinical and clinical pharmacology to evaluate new therapies and novel trial designs and improve outcome for children with catastrophic diseases.


Ryuma Tanaka

Nationwide Children’s Hospital / The Ohio State University College of Medicine

View Plenary Session 1

Biography

Ryuma Tanaka

Ryuma Tanaka, MD is a pediatric neuro-oncologist at Nationwide Children's Hospital and Assistant Professor of Pediatrics at The Ohio State University College of Medicine. His clinical and research interests focus on pediatric brain tumors, molecular diagnostics, precision oncology, immunotherapy and targeted therapies. He is involved in clinical trials and translational research aimed at advancing personalized treatment strategies and improving outcomes for children with central nervous system tumors.


Noriko Mitsuiki

Health Science Research and Development Center (HeRD), Institute of Science Tokyo Hospital

View Plenary Session 1

Biography

Noriko Mitsuiki is a Specially Appointed Assistant Professor in Health Science Research and Development Center (HeRD) at Institute of Science Tokyo Hospital. She had been involved in the care of pediatric patients with cancer, hematologic diseases, and inborn errors of immunity as a pediatrician. She received her Ph.D. in Medicine from Tokyo Medical and Dental University in 2014. Before starting to work as a member of HeRD in 2026, she had 4 years of experience as a clinical reviewer in the Division of Oncology (New Drug V) at Pharmaceuticals and Medical Devices Agency (PMDA). She is currently interested in drug development for pediatric and rare disease patients.


Kentaro Takeda

Astellas Pharma Global Development, Inc.

View Plenary Session 1

Biography

Kentaro Takeda

Dr. Kentaro Takeda is a Senior Director, Head of innovative statistics at Astellas Pharma Global Development, Inc. His research interest covers Bayesian clinical trial designs, including dose-finding trials, basket trials, using real-world data, and oncology statistics. Dr. Takeda has published more than 70 peer-reviewed papers in the research area. Dr. Takeda is leading an innovative statistics group in Astellas and has implemented novel statistical approaches, including his proposed methods, in new drug developments. Dr. Takeda is also an associate editor of several academic journals.


Luyan Dai

G-Plume Group

View Plenary Session 1

Biography

Luyan Dai

Dr. Luyan Dai possesses nearly two decades of industrial experience in healthcare and pharmaceutical industry in both US and Asia. She is a long term industry advocator and recognized advisor for applications of complex innovative designs, Bayesian analysis, multi-region clinical trials, real-world data and evidence, AI intelligent applications and digital technology in healthcare.

In her earlier years, she worked at Pfizer Global Research & Development Center and Boehringer Ingelheim Medicine in the US, contributing to global projects for clinical development and regulatory submissions in therapeutic areas including the central nervous system, hepatitis C, respiratory, oncology, cardiovascular, and women's health.

Dr. Dai was relocated to China in 2012 to establish the biostatistics function for Boehringer Ingelheim China and grew the team size from 1 to over 20 members. Later she successfully integrated the team in Japan and led the Asia team that contributed to the clinical development, regulatory submissions and market launch of nearly 30 product indications in Asia-Pacific, Middle East and Africa countries. She also enhanced the team’s global competencies to lead statistical distributions for global development programs.

Since she left Boehringer Ingelheim, she worked at two start-up companies and made significant contributions for the companies in IPO listings on the Hong Kong Stock Exchange. In 2018, she joined Harbour Biomed as the head of clinical research, contributed to the product development strategies, established and led the clinical team, facilitated external partnership alliances for clinical projects, and successfully delivered the key clinical project milestones to realize the strategic growth of the company.

In 2020, she joined Yidu Tech as the vice president of strategy and innovation with a dual role as the chief statistics expert, responsible for governing and upgrading the business and team of the life science sector, leading the exploration of new initiatives and breakthrough advancement of strategic projects, and supervising and overseeing the strategic partnership for key deliverables.

Dr. Dai also served as a venture capital partner of YD Capital. Dr. Dai received a Ph.D. in statistics from the University of Missouri, USA, specializing in Bayesian statistical methodology and application research. She graduated from Fudan University, majoring in statistics.


Jingjing Ye

Founder and Principal Consultant, DataDoctor LLC

View presentation in Invited Session 8

Biography

Jingjing Ye

Dr. Jingjing Ye is a biopharmaceutical executive and former senior FDA regulatory leader with more than 20 years of experience, specializing in digital transformation, advanced analytics, and data-driven drug development. During her 10-year tenure at FDA, she has been the statistical lead in setting up multiple regulatory precedents and innovations, including companion diagnostics, AI-assisted imaging devices, benefit-risk assessment in primary screening test in CDRH, Bayesian analysis in pediatric extrapolation, external control in rare diseases and concurrent global review and decision (Project Orbis, Real-time Oncology Review (RTOR) and Assessment Aid) in CDER. Dr. Ye is an elected Fellow of the American Statistical Association (ASA). As a founder and principal consultant of DataDoctor LLC, Dr. Ye is driven by a commitment to improving patient outcomes and is passionate about multidisciplinary collaboration to advance innovations in drug development.


Vicky Qian Wu

Associate Professor of Biostatistics, Clinical Research Division, Fred Hutchinson Cancer Center

View Plenary Session 1

Biography

Vicky Qian Wu

Qian “Vicky” Wu is an Associate Professor of Biostatistics, Clinical Research Division at Fred Hutchinson Cancer Center. Vicky received her Ph.D. in Biostatistics at University of Pennsylvania and M.S. in Biostatistics at UCLA. Vicky’s research focuses on biomarker analysis, statistical genetics, and clinical trials, with particular emphasis on CAR-T immunotherapy studies. She has served as lead biostatistician for more than 30 CAR-T trials at Fred Hutch and Seattle Children’s. Her methodology work includes high-dimensional biomarker analysis for small sample size, survival analysis with time-varying covariates, and epigenetic data analysis. She also develops open-source R tools, including TrialSize, CNVtest, ChIPtest, Spacelog, HDI_Shiny, TVCurves, SampleN, etc, to make advanced methods more accessible to cancer researchers.


Haitao Pan

Associate Member, Department of Biostatistics, St. Jude Children's Research Hospital

View organizer and moderator profile in Plenary Session 1

Biography

Haitao Pan

Dr. Haitao Pan is an Associate Member in the Department of Biostatistics at St. Jude Children's Research Hospital. His research focuses on developing innovative statistical methods for clinical trial design, evidence generation, and treatment decision-making, particularly in pediatric oncology and rare cancers.

His methodological interests include Bayesian adaptive clinical trial designs, dose optimization, external controls, causal inference, and the integration of evidence from clinical trials and real-world data.

At St. Jude, he chairs the Clinical Trials Design Forum (CTDF), an institutional committee responsible for the early-stage scientific and statistical review of clinical trial concepts, and serves on the Clinical Trials Scientific Review Committee (CTSRC).

Dr. Pan also serves as a statistician for the New Approaches to Neuroblastoma Therapy (NANT) consortium and is a member of the PCDC International Neuroblastoma Risk Group (INRG) Committee. He holds adjunct faculty appointments at Florida State University and the University of Memphis.

He has authored more than 70 peer-reviewed publications, published a book with Springer Nature, and developed 18 R software packages supporting clinical trial design and statistical analysis.


Ji-bin Li

Department of Clinical Research, Sun Yat-sen University Cancer Center, Guangzhou, China

View presentation in Invited Session 8

Biography

Ji-bin Li

Ji-Bin Li is a Professor of Biostatistics and Clinical Research Methodology in the Department of Clinical Research at the Sun Yat-sen University Cancer Center, Guangzhou, China. He has served as a statistician and methodologist on a series of cancer trials. His research focuses on biostatistical methods for clinical trials and longitudinal studies, with particular expertise in trial design, longitudinal data modeling, survival analysis, and regulatory science. He has published more than 40 peer-reviewed articles as first or corresponding author, in journals including Nature. His work has been cited more than 8,000 times, with an h-index of 49 (Google Scholar). He is the chief editor of the textbook Clinical Research Methodology (1st and 2nd editions) and has contributed to more than ten other textbooks and monographs. He was named to the Stanford University/Elsevier list of the World’s Top 2% Scientists in 2025 and 2026.


Jingwen Zhang

Department of Biomedical Statistics, The University of Osaka

View presentation in Invited Session 8

Biography

Jingwen Zhang

Jingwen Zhang is a PhD student in the Department of Biomedical Statistics at the University of Osaka. Her research focuses on statistical methodology for clinical trials, particularly the design and analysis of recurrent event outcomes. She has an undergraduate background in medicine and holds a Master of Public Health (MPH) degree, with a focus on cardiovascular epidemiology.


Zheng Chen

Lead of Keiji AI Japan; Associate Professor, The University of Osaka

View presentation and abstract: Multimodal AI Analysis Reveals Distinct Cancer Molecular Subtypes with Genomic and Epigenetic Interpretation

Biography

Zheng Chen

Dr. Zheng Chen is the lead of Keiji AI Japan and an Associate Professor at the University of Osaka, specializing in artificial intelligence for biomedical research and drug development. His research focuses on multimodal representation learning, cancer multi-omics integration, and AI-driven analysis of complex biological and clinical data. He has published research in leading venues, including Nature Machine Intelligence, Nature Biomedical Engineering, NeurIPS, and ICLR. His work bridges cutting-edge AI research and real-world applications in precision oncology and clinical studies.


Ying Yuan

The University of Texas MD Anderson Cancer Center

View presentation in Invited Session 7 · View panel in Plenary Session 2

Biography

Ying Yuan

Ying Yuan is the Bettyann Asche Murray Distinguished Professor and Chair of the Department of Biostatistics at the University of Texas MD Anderson Cancer Center. Dr. Yuan is internationally renowned for his pioneering research in innovative Bayesian adaptive designs, including early-phase trials, seamless trials, biomarker-guided trials, hybrid control trials, Bayesian borrowing of historical data, and surrogate endpoints. The designs and software developed by Dr. Yuan’s lab (www.trialdesign.org) have been widely adopted by medical research institutes and pharmaceutical companies. Among these, the BOIN design, developed by Dr. Yuan’s team, is a groundbreaking oncology dose-finding method recognized by the FDA as a fit-for-purpose drug development tool. The BOP2 design is also widely used for efficacy and toxicity monitoring in early phase trials. Dr. Yuan is a member of the FDA Advisory Committee for Genetic Metabolic Diseases, an elected Fellow of the American Statistical Association, and the lead author of two books: Bayesian Designs for Phase I-II Clinical Trials and Model-Assisted Bayesian Designs for Dose Finding and Optimization, both published by Chapman & Hall/CRC.